D-0548-2024 Class II Ongoing

Recalled by Imprimis NJOF, LLC — Ledgewood, NJ

FDA drug recall D-0548-2024 was initiated by Imprimis NJOF, LLC on May 14, 2024 and is designated Class II. Reason for recall: Lack of Assurance of Sterility The recall status is ongoing. Affected quantity: 4,280 boxes.

Recall details

Product Type
Drugs
Report Date
Jun 19, 2024
Initiation Date
May 14, 2024
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
4,280 boxes

Product description

Prednisolone-Moxifloxacin-Bromfenac Sterile Ophthalmic Suspension, 1%, 0.5%, 0.075%, 5mL, Quantity: 20mL, Rx Only, Compounded by: Imprimis NJOF, LLC. 1705 Route 46 West, Unit 6B Ledgewood, NJ NDC 71384-310-05

Reason for recall

Lack of Assurance of Sterility

Distribution pattern

US Nationwide

Code information

Lot: 23NOV018 Exp. 6/17/24

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0548-2024
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0548-2024. Report a data issue: hello@regdatalab.com.